Contact Us

Platform

Innovative Science, Transformative Potential

The Angiopep Advantage

B³ Pharma is harnessing the power of its Angiopep technology to overcome the toughest barriers in medicine. From enabling targeted drug delivery across the blood-brain barrier, to offering a versatile platform adaptable to multiple CNS therapeutic areas, and advancing a promising pipeline of Angiopep drug conjugates. 

Angiopep PDC

Angiopep PDC enables safe, targeted delivery across the blood-brain barrier via the LRP-1 receptor.

Learn More

Versatility

The Angiopep Platform leverages the LRP-1 receptor to deliver therapies across the blood-brain barrier and into target cells, with applications in both CNS disorders and multiple brain metastases. Its versatility allows conjugation with a wide range of molecules, from small drugs to antibodies and nanoparticles.

Learn More

Pipeline

B³ Pharma’s clinical pipeline is led by ANG1005 for brain metastases, with additional Angiopep conjugates in oncology, CNS, and pain, demonstrating the platform’s broad therapeutic potential.

Learn More